Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-25-123680
Filing Date
2025-05-21
Accepted
2025-05-21 08:45:49
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A d921291ddefa14a.htm DEFA14A 12781
2 GRAPHIC g921291page006.jpg GRAPHIC 328888
3 GRAPHIC g921291page007.jpg GRAPHIC 447270
  Complete submission text file 0001193125-25-123680.txt   1083347
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33038 | Film No.: 25970994
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)